Research Reports

Key takeaways

David M. Reese retiring as EVP and Chief Technology Officer on June 30, 2026.

Responsibilities redistributed to James E. Bradner, Murdo Gordon, and Peter H. Griffith effective June 1, 2026.

Sean Bruich appointed Senior Vice President and Chief Technology Officer effective June 1, 2026.

Changes aim to integrate science, technology, data, and align commercial, medical, policy teams.

Reese retirement eligible; will receive standard company retirement benefits.

James Bradner role updated to EVP, Research and Development, Artificial Intelligence and Data.

Full analysis

Amgen's announcement of David M. Reese's retirement from the EVP and Chief Technology Officer role reflects a planned leadership transition to enhance integration of science, technology, data, and alignment across commercial, medical, and policy functions. Reese, who joined in 2005 and drove AI adoption in R&D, will depart retirement-eligible on June 30, 2026, receiving standard benefits. Effective June 1, his duties shift to James E. Bradner (expanded R&D/AI/data role), Murdo Gordon (global markets/policy), and Peter H. Griffith (CFO), signaling distributed leadership in technology. New CTO Sean Bruich, a data science expert, will lead AI capabilities. These changes support Amgen's 'convergent innovation' strategy, positioning the company to accelerate medicine development and patient engagement through biology and advanced technologies.

AMGN · Amgen Inc.

Summary

Key takeaways

Full analysis